The peroxisome proliferators represent an important group of hepatic carcinogens in rodents that act via the nuclear receptor PPARα. The primary role of PPARα in mediating this response had led to the further characterization of potential events downstream that likely enable the carcinogenic response, including increased peroxisomal fatty acid beta oxidation and the modulation of hepatocellular replication and death, either generally or in preneoplastic lesions. A cooperative role of Kupffer cell activation has been proposed to function in the modulation of hepatocellular proliferation in rodent liver by peroxisome proliferators, but data that confirm or refute this proposal are mixed. Presently there is no evidence that links the Kupffer cell activation by peroxisome proliferators directly to the development of liver tumors. There are marked species differences in susceptibility to peroxisomal proliferation, and active investigation concerning the molecular basis of these differences continues.
Anderson, S.P., Dunn, C.S., Cattley, R., and Corton, J.C. (2001). Hepatocellular proliferation in response to a peroxisome proliferator does not require tnfα signaling. Carcinogenesis22, 1843—51.
2.
Ashby, J., Brady, A., Elcombe, C.R., Elliott, B.M., Ishmael, J., Odum, J., Tugwood, J.D., Kettle, S., and Purchase, I.F.H. (1994). Mechanisticallybased human hazard assessment of peroxisome proliferator-induced hepatocarcinogenesis . Human Exper Toxicol13(2), S1—117.
3.
Blumcke, S., Schwartzkopff, W., Lobeck, H., Edmondson, N.A., Prentice, D.E., and Blane, G.F. (1983). Influence of fenofibrate on cellular and subcellular liver structure in hyperlipidemic patients. Atherosclerosis46(1), 105—16.
4.
Bojes, H.K., Germolec, D.R., Simeonova, P., Bruccoleri, A., Schoonhoven, R., Luster, M.I., and Thurman, R.G. (1997). Antibodies to tumor necrosis factor alpha prevent increases in cell replication in liver due to the potent peroxisome proliferator, WY-14,643. Carcinogenesis18, 669—74.
5.
Bojes, H.K., and Thurman, R.G. (1996). Peroxisome proliferators activate Kupffer cells in vivo. Cancer Res56, 1—4.
6.
Bunger, M.K., Moran, S.M., Glover, E., Thomae, T.L., Lahvis, G.P., and Lin, B.C. (2003). Resistance to 2,3,7,8-tetrachlorodibenzo-p-dioxin toxicity and abnormal liver development in mice carrying a mutation in the nuclear localization sequence of the aryl hydrocarbon receptor. J Biol Chem278(20), 17767—74.
7.
Butler, E.G., England, P.J., and Williams, G.M. (1988). Genetic differences in enzymes associated with peroxisome proliferation and hydrogen peroxide metabolism in inbred mouse strains. Carcinogenesis9(8), 1459—63.
8.
Butler, E.G., Tanaka, T., Ichida, T., Maruyama, H., Leber, A.P., and Williams, G.M. (1988). Induction of hepatic peroxisome proliferation in mice by lactofen, a diphenyl ether herbicide. Toxicol Appl Pharmacol93(1), 72—80.
9.
Cattley, R.C. (2003). Regulation of cell proliferation and cell death by peroxisome proliferators. Micros Res Tech61(2), 179—84.
10.
Cattley, R.C., DeLuca, J., Elcombe, C., Fenner-Crisp, P., Lake, B.G., Marsman, D.S., Pastoor, T.A., Popp, J.A., Robinson, D.E., Schwetz, B., Tugwood, J., and Wahli, W. (1998). Do peroxisome proliferating compounds pose a hepatocarcinogenic hazard to humans? Regul Toxicol Pharmacol27(1), 47—60.
11.
Choudhury, A.I., Chahal, S., Bell, A.R., Tomlinson, S.R., Roberts, R.A., Salter, A.M., and Bell, D.R. (2000). Species differences in peroxisome proliferation; mechanisms and relevance. Mutat Res448, 201—12.
12.
Conway, J.G., Neptun, D.A., Garvey, L.K., and Popp, J.A. (1978). Role of fatty acyl coenzyme A oxidase in the efflux of oxidized glutathione from perfused livers of rats treated with the peroxisome proliferator nafenopin. Cancer Res47(18), 4795—800.
13.
Conway, J.G., Tomaszewski, K.E., Olson, M.J., Cattley, R.C., Marsman, D.S., and Popp, J.A. (1989). Relationship of oxidative damage to the hepatocarcinogenicity of the peroxisome proliferators di(2-ethylhexyl)phthalate and Wy-14,643. Carcinogenesis10(3), 513—9.
14.
Cressman, D.E., Greenbaum, L.E., Deangelis, R.A., Ciliberto, G., Furth, E.E., Poli, V., and Taub, R. (1996). Liver failure and defective hepatocyte regeneration in interleukin-6-deficient mice. Science274(5291), 1379—83.
15.
de la Iglesia, F.A., Lewis, J.E., Buchanan, R.A., Marcus, E.L., and McMahon, G. (1982). Light and electron microscopy of liver in hyperlipoproteinemic patients under long-term gemfibrozil treatment. Atherosclerosis43(1), 19—37.
Diehl, A.M. (2000). Cytokine regulation of liver injury and repair . Immunol Rev174, 160—71.
18.
Escher, P., and Wahli, W. (2000). Peroxisome proliferator-activated receptors: insight into multiple cellular functions. Mutation Research448(2), 121—38.
19.
Fausto, N. (2000). Liver regeneration. J Hepatol32(Suppl. 1), 19—31.
20.
Galloway, S.M., Johnson, T.E., Armstrong, M.J., and Ashby, J. (2000). The genetic toxicity of the peroxisome proliferator class of rodent hepatocarcinoge. Mutat Res448(2), 153—8.
21.
Gariot, P., Barrat, E., Drouin, P., Genton, P., Pointel, J.P., Foliguet, B., Kolopp, M., and Debry, G. (1987). Morphometric study of human hepatic cell modifications induced by fenofibrate. Metabolism: Clin Exper36(3), 203— 10.
22.
Gervois, P., Pineda, T.I., Chinetti, G., Grotzinger, T., Dubois, G., Fruchart, J.C., Fruchart-Najib, J., Leitersdorf, E., and Staels, B. (1999). A truncated human peroxisome proliferator-activated receptor alpha splice variant with dominant negative activity. Mol Endocrinol13(9), 1535—49.
23.
Gibson, G.G., Orton, T.C., and Tamburini, P.P. (1982). Cytochrome P-450 induction by clofibrate. Purification and properties of a hepatic cytochrome P-450 relatively specific for the 12- and 11-hydroxylation of dodecanoic acid (lauric acid). Biochem J203(1), 161—8.
24.
Hanefeld, M., Kemmer, C., and Kadner, E. (1983). Relationship between morphological changes and lipid-lowering action of p-chlorphenoxyisobutyric acid (CPIB) on hepatic mitochondria and peroxisomes in man. Atherosclerosis46(2), 239—46.
25.
Hess, R., Staubli, W., and Riess, W. (1965). Nature of the hepatomegalic effect produced by ethyl-chlorophenoxy-isobutyrate in the rat. Nature208(13), 856—8.
26.
Issemann, I., and Green, S. (1990). Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature347(6294), 645—50.
27.
Issemann, I., Prince, R.A., Tugwood, J.D., and Green, S. (1993). The peroxisome proliferator-activated receptor: retinoid X receptor heterodimer is activated by fatty acids and fibrate hypolipidaemic drugs. J Mol Endocrinol11(1), 37—47.
28.
Kakizaki, S., Yamamoto, Y., Ueda, A., Moore, R., Sueyoshi, T., and Negishi, M. (2003). Phenobarbital induction of drug/steroid-metabolizing enzymes and nuclear receptor CAR. Biochim Biophys Acta1619(3), 239—42.
29.
Kluwe, W.M., Haseman, J.K., Douglas, J.F., and Huff, J.E. (1982). The carcinogenicity of dietary di(2-ethylhexyl) phthalate (DEHP) in Fischer 344 rats and B6C3F1 mice. J Toxicol Environ Health10(4—5), 797— 815.
30.
Kurata, Y., Kidachi, F., Yokoyama, M., Toyota, N., Tsuchitani, M., and Katoh, M. (1998). Subchronic toxicity of Di(2-ethylhexyl)phthalate in common marmosets: lack of hepatic peroxisome proliferation, testicular atrophy, or pancreatic acinar cell hyperplasia. Toxicol Sci42, 49—56.
31.
Lake, B.G., Evans, J.G., Cunninghame, M.E., and Price, R.J. (1993). Comparison of the hepatic effects of nafenopin and WY-14,643 on peroxisome proliferation and cell replication in the rat and Syrian hamster. Environ Health Perspect101(5), 241—7.
32.
Lake, B.G., Rumsby, P.C., Price, R.J., and Cunninghame, M.E. (2000). Species differences in hepatic peroxisome proliferation, cell replication and transforming growth factor-beta1 gene expression in the rat, Syrian hamster and guinea pig. Mut Res448(2), 213—25.
33.
Lambe, K.G., Woodyatt, N.J., Macdonald, N., Chevalier, S., and Roberts, R.A. (1999). Species differences in sequence and activity of the peroxisome proliferator response element (PPRE) within the acyl CoA oxidase gene promoter. Toxicol Lett110(1—2), 119—27.
34.
Lawrence, J.W., Wollenberg, G.K., and DeLuca, J.G. (2001). Tumor necrosis factor alpha is not required for WY14,643-induced cell proliferation. Carcinogenesis22, 381—6.
35.
Lazarow, P.B., and De Duve, C. (1976). A fatty acyl-CoA oxidizing system in rat liver peroxisomes; enhancement by clofibrate, a hypolipidemic drug. Proc Nat Acad Sci USA73(6), 2043—6.
36.
Ledda-Columbano, G.M., Curto, M., Piga, R., Zedda, A.I., Menegazzi, M., Sartori, C., Shinozuka, H., Bluethmann, H., Poli, V., and Columbano, A. (1998). In vivo hepatocyte proliferation is inducible through a TNF and IL-6-independent pathway. Oncogene17, 1039—44.
37.
Lee, S.S., Pineau, T., Drago, J., Lee, E.J., Owens, J.W., Kroetz, D.L., Fernandez-Salguero, P.M., Westphal, H., and Gonzalez, F.J. (1995). Targeted disruption of the alpha isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators. Mol Cell Biol15, 3012—22.
38.
Marsman, D.S. (1991). Peroxisome Proliferator Hepatocarcinogenesis in Rats, Dissertation, University of North Carolina, Chapel Hill, NC.
39.
Marsman, D.S., Cattley, R.C., Conway, J.G., and Popp, J.A. (1988). Relationship of hepatic peroxisome proliferation and replicative DNA synthesis to the hepatocarcinogenicity of the peroxisome proliferators di(2-ethylhexyl)phthalate and [4-chloro-6-(2,3-xylidino)-2-pyrimidinylthio]acetic acid (Wy-14,643) in rats. Cancer Res48, 6739—44.
40.
Marsman, D.S., Goldsworthy, T.L., and Popp, J.A. (1992). Contrasting hepatocytic peroxisome proliferation, lipofuscin accumulation and cell turnover for the hepatocarcinogens Wy-14,643 and clofibric acid. Carcinogenesis13, 1011—7.
41.
Miller, R.T., Anderson, S.P., Corton, J.C., and Cattley, R.C. (2000). Apoptosis, mitosis and cyclophilin-40 expression in regressing peroxisome proliferator-induced adenomas. Carcinogenesis21, 647— 52.
42.
Palmer, C.N., Hsu, M.H., Griffin, K.J., Raucy, J.L., and Johnson, E.F. (1998). Peroxisome proliferator activated receptor-alpha expression in human liver. Mol Pharmacol53, 14—22.
43.
Peters, J.M., Cattley, R.C., and Gonzalez, F.J. (1997). Role of PPAR alpha in the mechanism of action of the nongenotoxic carcinogen and peroxisome proliferator Wy-14,643. Carcinogenesis18, 2029—33.
44.
Pugh, G., Isenberg, J.S., Kamendulis, L.M., Ackley, D.C., Clare, L.J., Brown, R., Lington, A.W., Smith, J.H., and Klaunig, J.E. (2000). Effects of di-isononyl phthalate, di-2-ethylhexyl phthalate, and clofibrate in cynomolgus monkeys. Toxicol Sci56(1), 181—8.
45.
Reddy, J.K., Azarnoff, D.L., and Hignite, C.E. (1980). Hypolipidaemic hepatic peroxisome proliferators form a novel class of chemical carcinogens. Nature283(5745), 397—8.
46.
Reddy, J.K., Azarnoff, D.L., Svoboda, D.J., and Prasad, J.D. (1974). Nafenopin induced hepatic microbody peroxisome proliferation and catalase synthesis in rats and mice absence of sex difference in response. J Cell Biol61(2), 344—58.
47.
Roberts, R.A. (2002). Evidence for cross talk between PPARalpha and p38 MAP kinase. Toxicol Sci68(2), 270—4.
48.
Roglans, N., Bellido, A., Rodriguez, C., Cabrero, A., Novell, F., Ros, E., Zambon, D., and Laguna, J.C. (2002). Fibrate treatment does not modify the expression of acyl coenzyme A oxidase in human liver. Clini Pharmacol Ther72(6), 692—701.
49.
Rose, M.L., Germolec, D.R., Schoonhoven, R., and Thurman, R.G. (1997). Kupffer cells are causally responsible for the mitogenic effect of peroxisome proliferators. Carcinogenesis18, 1453—6.
50.
Rusyn, I., Tsukamoto, H., and Thurman, R.G. (1998). WY-14 643 rapidly activates nuclear factor kappaB in Kupffer cells before hepatocytes. Carcinogenesis19, 1217—22.
51.
Rusyn, I., Yamashina, S., Segal, B.H., Schoonhoven, R., Holland, S.M., Cattley, R.C., Swenberg, J.A., and Thurman, R.G. (2000). Oxidants from nicotinamide adenine dinucleotide phosphate oxidase are involved in triggering cell proliferation in the liver due to peroxisome proliferators. Cancer Res60, 4798—803.
52.
Tanaka, K., Smith, P.F., Stromberg, P.C., Eydelloth, R.S., Herold, E.G., Grossman, S.J., Frank, J.D., Hertzog, P.R., Soper, K.A., and Keenan, K.P. (1992). Studies of early hepatocellular proliferation and peroxisomal proliferation in Sprague—Dawley rats treated with tumorigenic doses of clofibrate. Toxicol Appl Pharmacol116, 71—7.
53.
Taub, R., Greenbaum, L.E., and Peng, Y. (1999). Transcriptional regulatory signals define cytokine-dependent and -independent pathways in liver regeneration. Semin Liver Dis19, 117—27.
54.
Tugwood, J.D., Issemann, I., Anderson, R.G., Bundell, K.R., McPheat, W.L., and Green, S. (1992). The mouse peroxisome proliferator activated receptor recognizes a response element in the 5' flanking sequence of the rat acyl CoA oxidase gene. EMBO J11(2), 433—9.
55.
Wallenius, V., Wallenius, K., and Jansson, J.O. (2000). Normal pharmacologically-induced, but decreased regenerative liver growth in interleukin-6-deficient (IL-6−/−) mice. J Hepatol33(6), 967—74.
56.
Ward, J.M., Peters, J.M., Perella, C.M., and Gonzalez, F.J. (1998). Receptor and nonreceptor-mediated organ-specific toxicity of di(2-ethylhexyl)phthalate (DEHP) in peroxisome proliferator-activated receptor alpha-null mice. Toxicol Pathol26, 240—6.
57.
Wong, C.W., McNally, C., Nickbarg, E., Komm, B.S., and Cheskis, B.J. (2002). Estrogen receptor-interacting protein that modulates its nongenomic activity-crosstalk with Src/Erk phosphorylation cascade. Proc Natl Acad Sci USA99(23), 14783—8.
58.
Woodyatt, N.J., Lambe, K.G., Myers, K.A., Tugwood, J.D., and Roberts, R.A. (1999). The peroxisome proliferator (PP) response element upstream of the human acyl CoA oxidase gene is inactive among a sample human population: significance for species differences in response to PPs. Carcinogenesis20(3), 369—72.
59.
Yamada, Y., and Fausto, N. (1998). Deficient liver regeneration after carbon tetrachloride injury in mice lacking type 1 but not type 2 tumor necrosis factor receptor . Hepatology28(4 PART 2), 401A.
60.
Yamada, Y., Kirillova, I., Peschon, J.J., and Fausto, N. (1997). Initiation of liver gowth by tumor necrosis factor: deficient liver regeneration in mice lacking type I tumor necrosis factor receptor. Med Sci94, 1441—6.
61.
Yeldandi, A.V., Rao, M.S., and Reddy, J.K. (2000). Hydrogen peroxide generation in peroxisome proliferator-induced oncogenesis. Mutat Res448(2), 159—77.
